Atopic Dermatitis (Eczema) Study

Enter your info and the study team will contact you soon!
Your data is securely stored and only shared with the research team
Logo Image
Age: 18+
Gender:
Any
Healthy Volunteers: No
Keywords: Atopic Dermatitis, Eczema
Type: Drug Study, Phase 3
Target:
15 Participants
Investigator:
Description
Baricitinib is a JAK inhibitor that targets immune molecules which contribute to atopic dermatitis. This mechanism makes baricitinib an effective agent to reduce inflammatory and autoimmune conditions. The trial will explore the effectiveness and safety of low and high dose baricitinib compared to placebo for the treatment of atopic dermatitis.
This study requires

Applicable patients should be diagnosed with moderate to severe atopic dermatitis according to the guidelines set by the American Academy of Dermatology. Study products will be taken orally in tablet-form daily. A more in-depth explanation of the study protocol and treatment overview will take place during initial screening.

Who can participate

Inclusion Criteria: Diagnosis of atopic dermatitis > 12 months; Moderate to severe atopic dermatitis with BSA >10%: Uncontrolled with topical corticosteriods OR failed systemic therapies (i.e., cyclosporine, methotrexate, azathioprine, or mycophenolate mofetil) within 6 months of screening

Exclusion Criteria: Patients who have documented: Other active concomitant skin conditions (ex: lupus, psoriasis); Current or recent serious medical condition or infection; Immunodeficiency; Concomitant illnesses requiring systemic corticosteriods; At risk for or history of blood clots in legs or lungs; Received a live vaccine within 12 weeks of Visit 2 or need to receive one during the study duration; Alcohol or drug abuse within the last 2 years of Visit 1; Pregnant or breast feeding

Compensation
Yes
Resources
Schedule
Study duration and period
16 visits over approximately 2 years
Recruitment period
Until Feb. 28, 2019
Location
UC Davis Dermatology
3301 C Street
Suite 1400
Sacramento, CA 95816